Antibody drug conjugates: Tackling the unsolved challenges with novel technologies
Antibody drug conjugates (ADCs) are currently at the forefront of cancer treatment, and while related R&D programmes, licensing agreements, and other investment has taken off in the biopharma sector, persistent drug development challenges around toxicity and payload sensitivity call for a new approach.
